;PMID: 6716512
;source_file_882.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..43] = [t:0..43]
;1)sentence:[e:49..196] = [t:49..196]
;2)section:[e:200..227] = [t:200..227]
;3)sentence:[e:231..327] = [t:231..327]
;4)sentence:[e:328..525] = [t:328..525]
;5)sentence:[e:527..600] = [t:527..600]
;6)sentence:[e:602..897] = [t:602..897]
;7)sentence:[e:898..1148] = [t:898..1148]
;8)sentence:[e:1149..1393] = [t:1149..1393]
;9)sentence:[e:1394..1553] = [t:1394..1553]
;10)sentence:[e:1554..1625] = [t:1554..1625]
;11)sentence:[e:1626..1825] = [t:1626..1825]
;12)sentence:[e:1826..1980] = [t:1826..1980]
;13)section:[e:1984..2028] = [t:1984..2028]

;section 0 Span:0..43
;J Toxicol Environ Health. 1984;13(1):69-81.
(SEC
  (FRAG (NNP:[0..1] J) (NNP:[2..9] Toxicol) (NNP:[10..17] Environ)
        (NNP:[18..24] Health) (.:[24..25] .) (CD:[26..30] 1984)
        (::[30..34] ;13-LRB-) (CD:[34..35] 1) (-RRB-:[35..36] -RRB-)
        (CD:[36..39] :69) (::[39..40] -) (CD:[40..42] 81) (.:[42..43] .)))

;sentence 1 Span:49..196
;Ascorbic acid potentiates the substrate-specific inhibition of mixed-function
; oxidation and the stimulation of NADPH oxidation caused by paraquat.
;[49..62]:substance:"Ascorbic acid"
;[79..88]:substance:"substrate"
;[161..166]:substance:"NADPH"
;[187..195]:substance:"paraquat"
(SENT
  (S-HLN
    (NP-SBJ (JJ:[49..57] Ascorbic) (NN:[58..62] acid))
    (VP (VBZ:[63..74] potentiates)
      (NP
        (NP
          (NP (DT:[75..78] the)
            (ADJP (NN:[79..88] substrate) (HYPH:[88..89] -)
                  (JJ:[89..97] specific))
            (NN:[98..108] inhibition))
          (PP (IN:[109..111] of)
            (NP
              (ADJP (JJ:[112..117] mixed) (HYPH:[117..118] -)
                    (NN:[118..126] function))
              (NN:[128..137] oxidation))))
        (CC:[138..141] and)
        (NP
          (NP (DT:[142..145] the) (NN:[146..157] stimulation))
          (PP (IN:[158..160] of)
            (NP
              (NP (NN:[161..166] NADPH) (NN:[167..176] oxidation))
              (VP (VBN:[177..183] caused)
                (NP (-NONE-:[183..183] *))
                (PP (IN:[184..186] by)
                  (NP-LGS (NN:[187..195] paraquat)))))))))
    (.:[195..196] .)))

;section 2 Span:200..227
;Montgomery MR, Shamblin PB.
(SEC
  (FRAG (NNP:[200..210] Montgomery) (NNP:[211..213] MR) (,:[213..214] ,)
        (NNP:[215..223] Shamblin) (NNP:[224..227] PB.)))

;sentence 3 Span:231..327
;Paraquat inhibits the in vitro hepatic microsomal metabolism of both 
;ethylmorphine and aniline.
;[231..239]:substance:"Paraquat"
;[301..314]:substance:"ethylmorphine"
;[319..326]:substance:"aniline"
(SENT
  (S
    (NP-SBJ (NN:[231..239] Paraquat))
    (VP (VBZ:[240..248] inhibits)
      (NP
        (NP (DT:[249..252] the)
          (ADJP (FW:[253..255] in) (FW:[256..261] vitro))
          (JJ:[262..269] hepatic) (JJ:[270..280] microsomal)
           (NN:[281..291] metabolism))
        (PP (IN:[292..294] of)
          (NP (CC:[295..299] both) (NN:[301..314] ethylmorphine)
              (CC:[315..318] and) (NN:[319..326] aniline)))))
    (.:[326..327] .)))

;sentence 4 Span:328..525
;Inclusion of ascorbate with paraquat in the  incubations did not alter the
;paraquat effect on ethylmorphine N-demethylase  activity but potentiated the
;inhibition of aniline p-hydroxylase activity.
;[341..350]:substance:"ascorbate"
;[356..364]:substance:"paraquat"
;[403..411]:substance:"paraquat"
;[422..449]:substance:"ethylmorphine N-demethylase"
;[494..515]:substance:"aniline p-hydroxylase"
(SENT
  (S
    (NP-SBJ
      (NP (NN:[328..337] Inclusion))
      (PP (IN:[338..340] of)
        (NP (NN:[341..350] ascorbate)))
      (PP (IN:[351..355] with)
        (NP (NN:[356..364] paraquat)))
      (PP-LOC (IN:[365..367] in)
        (NP (DT:[368..371] the) (NNS:[373..384] incubations))))
    (VP
      (VP (VBD:[385..388] did) (RB:[389..392] not)
        (VP (VB:[393..398] alter)
          (NP
            (NP (DT:[399..402] the) (NN:[403..411] paraquat)
                (NN:[412..418] effect))
            (PP (IN:[419..421] on)
              (NP
                (NML (NN:[422..435] ethylmorphine) (NN:[436..449] N-demethylase))
                (NN:[451..459] activity))))))
      (CC:[460..463] but)
      (VP (VBD:[464..475] potentiated)
        (NP
          (NP (DT:[476..479] the) (NN:[480..490] inhibition))
          (PP (IN:[491..493] of)
            (NP
              (NML (NN:[494..501] aniline) (NN:[502..515] p-hydroxylase))
              (NN:[516..524] activity))))))
    (.:[524..525] .)))

;sentence 5 Span:527..600
;Ascorbate alone was without effect on the metabolism of either substrate.
;[527..536]:substance:"Ascorbate"
;[590..599]:substance:"substrate"
(SENT
  (S
    (NP-SBJ
      (NP (NN:[527..536] Ascorbate))
      (ADJP (JJ:[537..542] alone)))
    (VP (VBD:[543..546] was)
      (PP-PRD (IN:[547..554] without)
        (NP
          (NP (NN:[555..561] effect))
          (PP (IN:[562..564] on)
            (NP
              (NP (DT:[565..568] the) (NN:[569..579] metabolism))
              (PP (IN:[580..582] of)
                (NP (DT:[583..589] either) (NN:[590..599] substrate))))))))
    (.:[599..600] .)))

;sentence 6 Span:602..897
;Paraquat stimulated the hepatic microsomal oxidation of nicotinamide adenine 
;dinucleotide phosphate (NADPH) equally in the absence of mixed-function
;oxidase  (MFO) substrates or in the presence of ethylmorphine; in the
;presence of aniline  the rate of NADPH oxidation was significantly greater.
;[602..610]:substance:"Paraquat"
;[658..702]:substance:"nicotinamide adenine  dinucleotide phosphate"
;[704..709]:substance:"NADPH"
;[737..759]:substance:"mixed-function oxidase"
;[762..765]:substance:"MFO"
;[767..777]:substance:"substrates"
;[800..813]:substance:"ethylmorphine"
;[834..841]:substance:"aniline"
;[855..860]:substance:"NADPH"
(SENT
  (S
    (S
      (NP-SBJ (NN:[602..610] Paraquat))
      (VP (VBD:[611..621] stimulated)
        (NP
          (NP (DT:[622..625] the) (JJ:[626..633] hepatic)
              (JJ:[634..644] microsomal) (NN:[645..654] oxidation))
          (PP (IN:[655..657] of)
            (NP
              (NP (NN:[658..670] nicotinamide) (NN:[671..678] adenine)
                  (NN:[680..692] dinucleotide) (NN:[693..702] phosphate))
              (NP (-LRB-:[703..704] -LRB-) (NN:[704..709] NADPH)
                  (-RRB-:[709..710] -RRB-)))))
        (ADVP (RB:[711..718] equally))
        (PP
          (PP (IN:[719..721] in)
            (NP
              (NP (DT:[722..725] the) (NN:[726..733] absence))
              (PP (IN:[734..736] of)
                (NP
                  (NML
                    (NML
                      (NML (JJ:[737..742] mixed) (HYPH:[742..743] -)
                           (NN:[743..751] function))
                      (NN:[752..759] oxidase))
                    (NML (-LRB-:[761..762] -LRB-) (NN:[762..765] MFO)
                         (-RRB-:[765..766] -RRB-)))
                  (NNS:[767..777] substrates)))))
          (CC:[778..780] or)
          (PP (IN:[781..783] in)
            (NP
              (NP (DT:[784..787] the) (NN:[788..796] presence))
              (PP (IN:[797..799] of)
                (NP (NN:[800..813] ethylmorphine))))))))
    (::[813..814] ;)
    (S
      (PP (IN:[815..817] in)
        (NP
          (NP (DT:[818..821] the) (NN:[822..830] presence))
          (PP (IN:[831..833] of)
            (NP (NN:[834..841] aniline)))))
      (NP-SBJ
        (NP (DT:[843..846] the) (NN:[847..851] rate))
        (PP (IN:[852..854] of)
          (NP (NN:[855..860] NADPH) (NN:[861..870] oxidation))))
      (VP (VBD:[871..874] was)
        (ADJP-PRD (RB:[875..888] significantly) (JJR:[889..896] greater)))
      (.:[896..897] .))))

;sentence 7 Span:898..1148
;Also, in the presence of  aniline, ascorbate potentiated the paraquat-induced
;NADPH oxidation, while it  was ineffective with paraquat on NADPH oxidation
;in the presence of  ethylmorphine or in the absence of substrates for the
;microsomal MFO system.
;[924..931]:substance:"aniline"
;[933..942]:substance:"ascorbate"
;[959..967]:substance:"paraquat"
;[976..981]:substance:"NADPH"
;[1024..1032]:substance:"paraquat"
;[1036..1041]:substance:"NADPH"
;[1072..1085]:substance:"ethylmorphine"
;[1107..1117]:substance:"substrates"
;[1137..1140]:substance:"MFO"
(SENT
  (S
    (ADVP (RB:[898..902] Also))
    (,:[902..903] ,)
    (PP (IN:[904..906] in)
      (NP
        (NP (DT:[907..910] the) (NN:[911..919] presence))
        (PP (IN:[920..922] of)
          (NP (NN:[924..931] aniline)))))
    (,:[931..932] ,)
    (NP-SBJ (NN:[933..942] ascorbate))
    (VP (VBD:[943..954] potentiated)
      (NP (DT:[955..958] the)
        (ADJP (NN:[959..967] paraquat) (HYPH:[967..968] -)
              (VBN:[968..975] induced))
        (NN:[976..981] NADPH) (NN:[982..991] oxidation))
      (,:[991..992] ,)
      (SBAR-ADV (IN:[993..998] while)
        (S
          (NP-SBJ (PRP:[999..1001] it))
          (VP (VBD:[1003..1006] was)
            (ADJP-PRD (JJ:[1007..1018] ineffective))
            (PP (IN:[1019..1023] with)
              (NP (NN:[1024..1032] paraquat)))
            (PP (IN:[1033..1035] on)
              (NP (NN:[1036..1041] NADPH) (NN:[1042..1051] oxidation)))
            (PP
              (PP (IN:[1052..1054] in)
                (NP
                  (NP (DT:[1055..1058] the) (NN:[1059..1067] presence))
                  (PP (IN:[1068..1070] of)
                    (NP (NN:[1072..1085] ethylmorphine)))))
              (CC:[1086..1088] or)
              (PP (IN:[1089..1091] in)
                (NP
                  (NP (DT:[1092..1095] the) (NN:[1096..1103] absence))
                  (PP (IN:[1104..1106] of)
                    (NP
                      (NP (NNS:[1107..1117] substrates))
                      (PP (IN:[1118..1121] for)
                        (NP (DT:[1122..1125] the) (JJ:[1126..1136] microsomal)
                            (NN:[1137..1140] MFO) (NN:[1141..1147] system))))))))))))
    (.:[1147..1148] .)))

;sentence 8 Span:1149..1393
;The  potentiated inhibition of aniline metabolism, concomitant with the
;potentiated  stimulation of NADPH oxidation, was consistent whether liver
;microsomal  fractions were prepared from control rats or from animals induced
;with  phenobarbital.
;[1180..1187]:substance:"aniline"
;[1249..1254]:substance:"NADPH"
;[1379..1392]:substance:"phenobarbital"
(SENT
  (S
    (NP-SBJ
      (NP
        (NP (DT:[1149..1152] The) (JJ:[1154..1165] potentiated)
            (NN:[1166..1176] inhibition))
        (PP (IN:[1177..1179] of)
          (NP (NN:[1180..1187] aniline) (NN:[1188..1198] metabolism))))
      (,:[1198..1199] ,)
      (ADJP (JJ:[1200..1211] concomitant)
        (PP (IN:[1212..1216] with)
          (NP
            (NP (DT:[1217..1220] the) (JJ:[1221..1232] potentiated)
                (NN:[1234..1245] stimulation))
            (PP (IN:[1246..1248] of)
              (NP (NN:[1249..1254] NADPH) (NN:[1255..1264] oxidation)))))))
    (,:[1264..1265] ,)
    (VP (VBD:[1266..1269] was)
      (ADJP-PRD (JJ:[1270..1280] consistent)
        (SBAR (IN:[1281..1288] whether)
          (S
            (NP-SBJ-1 (NN:[1289..1294] liver) (JJ:[1295..1305] microsomal)
                      (NNS:[1307..1316] fractions))
            (VP (VBD:[1317..1321] were)
              (VP (VBN:[1322..1330] prepared)
                (NP-1 (-NONE-:[1330..1330] *))
                (PP
                  (PP (IN:[1331..1335] from)
                    (NP (NN:[1336..1343] control) (NNS:[1344..1348] rats)))
                  (CC:[1349..1351] or)
                  (PP (IN:[1352..1356] from)
                    (NP
                      (NP (NNS:[1357..1364] animals))
                      (VP (VBN:[1365..1372] induced)
                        (NP (-NONE-:[1372..1372] *))
                        (PP-MNR (IN:[1373..1377] with)
                          (NP (NN:[1379..1392] phenobarbital)))))))))))))
    (.:[1392..1393] .)))

;sentence 9 Span:1394..1553
;Investigation of possible influences on NADPH cytochrome c  reductase
;activity was precluded by the rapid nonenzymatic reduction of  cytochrome c
;by ascorbate.
;[1434..1463]:substance:"NADPH cytochrome c  reductase"
;[1527..1539]:cyp450:"cytochrome c"
;[1543..1552]:substance:"ascorbate"
(SENT
  (S
    (NP-SBJ-1
      (NP (NN:[1394..1407] Investigation))
      (PP (IN:[1408..1410] of)
        (NP
          (NP (JJ:[1411..1419] possible) (NNS:[1420..1430] influences))
          (PP (IN:[1431..1433] on)
            (NP
              (NML (NN:[1434..1439] NADPH)
                (NML (NN:[1440..1450] cytochrome) (NN:[1451..1452] c))
                (NN:[1454..1463] reductase))
              (NN:[1464..1472] activity))))))
    (VP (VBD:[1473..1476] was)
      (VP (VBN:[1477..1486] precluded)
        (NP-1 (-NONE-:[1486..1486] *))
        (PP (IN:[1487..1489] by)
          (NP-LGS
            (NP (DT:[1490..1493] the) (JJ:[1494..1499] rapid)
                (JJ:[1500..1512] nonenzymatic) (NN:[1513..1522] reduction))
            (PP (IN:[1523..1525] of)
              (NP (NN:[1527..1537] cytochrome) (NN:[1538..1539] c)))
            (PP (IN:[1540..1542] by)
              (NP (NN:[1543..1552] ascorbate)))))))
    (.:[1552..1553] .)))

;sentence 10 Span:1554..1625
;The paraquat-ascorbate redox couple would not reduce  cytochrome P-450.
;[1558..1566]:substance:"paraquat"
;[1567..1576]:substance:"ascorbate"
;[1608..1624]:cyp450:"cytochrome P-450"
(SENT
  (S
    (NP-SBJ (DT:[1554..1557] The)
      (NML (NN:[1558..1566] paraquat) (HYPH:[1566..1567] -)
           (NN:[1567..1576] ascorbate))
      (NN:[1577..1582] redox) (NN:[1583..1589] couple))
    (VP (MD:[1590..1595] would) (RB:[1596..1599] not)
      (VP (VB:[1600..1606] reduce)
        (NP (NN:[1608..1618] cytochrome) (NN:[1619..1624] P-450))))
    (.:[1624..1625] .)))

;sentence 11 Span:1626..1825
;These data suggest that a paraquat interaction with the active  microsomal
;MFO enzyme system plays a role in the depletion of cellular NADPH  stores
;that occurs after paraquat administration in vivo.
;[1652..1660]:substance:"paraquat"
;[1701..1711]:substance:"MFO enzyme"
;[1761..1766]:substance:"NADPH"
;[1793..1801]:substance:"paraquat"
(SENT
  (S
    (NP-SBJ (DT:[1626..1631] These) (NNS:[1632..1636] data))
    (VP (VBP:[1637..1644] suggest)
      (SBAR (IN:[1645..1649] that)
        (S
          (NP-SBJ
            (NP (DT:[1650..1651] a) (NN:[1652..1660] paraquat)
                (NN:[1661..1672] interaction))
            (PP (IN:[1673..1677] with)
              (NP (DT:[1678..1681] the) (JJ:[1682..1688] active)
                  (JJ:[1690..1700] microsomal)
                 (NN:[1701..1704] MFO) (NN:[1705..1711] enzyme)
                (NN:[1712..1718] system))))
          (VP (VBZ:[1719..1724] plays)
            (NP (DT:[1725..1726] a) (NN:[1727..1731] role))
            (PP (IN:[1732..1734] in)
              (NP
                (NP
                  (NP (DT:[1735..1738] the) (NN:[1739..1748] depletion))
                  (PP (IN:[1749..1751] of)
                    (NP (JJ:[1752..1760] cellular) (NN:[1761..1766] NADPH)
                        (NNS:[1768..1774] stores))))
                (SBAR
                  (WHNP-1 (WDT:[1775..1779] that))
                  (S
                    (NP-SBJ-1 (-NONE-:[1779..1779] *T*))
                    (VP (VBZ:[1780..1786] occurs)
                      (PP-TMP (IN:[1787..1792] after)
                        (NP (NN:[1793..1801] paraquat)
                            (NN:[1802..1816] administration)))
                      (ADVP (FW:[1817..1819] in) (FW:[1820..1824] vivo)))))))))))
    (.:[1824..1825] .)))

;sentence 12 Span:1826..1980
;This mechanism may  play a significant role in the development of paraquat
;toxicity and in the  potentiated toxicity observed with ascorbate and
;paraquat.
;[1892..1900]:substance:"paraquat"
;[1957..1966]:substance:"ascorbate"
;[1971..1979]:substance:"paraquat"
(SENT
  (S
    (NP-SBJ (DT:[1826..1830] This) (NN:[1831..1840] mechanism))
    (VP (MD:[1841..1844] may)
      (VP (VB:[1846..1850] play)
        (NP (DT:[1851..1852] a) (JJ:[1853..1864] significant)
            (NN:[1865..1869] role))
        (PP
          (PP (IN:[1870..1872] in)
            (NP
              (NP (DT:[1873..1876] the) (NN:[1877..1888] development))
              (PP (IN:[1889..1891] of)
                (NP (NN:[1892..1900] paraquat) (NN:[1901..1909] toxicity)))))
          (CC:[1910..1913] and)
          (PP (IN:[1914..1916] in)
            (NP
              (NP (DT:[1917..1920] the) (JJ:[1922..1933] potentiated)
                  (NN:[1934..1942] toxicity))
              (VP (VBN:[1943..1951] observed)
                (NP (-NONE-:[1951..1951] *))
                (PP (IN:[1952..1956] with)
                  (NP (NN:[1957..1966] ascorbate) (CC:[1967..1970] and)
                      (NN:[1971..1979] paraquat)))))))))
    (.:[1979..1980] .)))

;section 13 Span:1984..2028
;PMID: 6716512 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[1984..1988] PMID) (::[1988..1989] :) (CD:[1990..1997] 6716512)
        (NN:[1998..1999] -LSB-) (NNP:[1999..2005] PubMed) (::[2006..2007] -)
        (NN:[2008..2015] indexed) (IN:[2016..2019] for)
        (NNP:[2020..2028] MEDLINE-RSB-)))
